Patients with serious asthma who are not monitored with conventional treatment-leaving them at danger of serious asthma attacks-could benefit from a single inhaler combining three therapies instead of two, according to two phases 3 randomized controlled studies with over 2,500 patients in 17 nations, released in The Lancet and submitted concurrently at the European Respiratory Society.
Using various inhalers leaves patients attempting to avoid symptoms using equipment of distinct design, with distinct instructions and distinct dosing regimens (such as the number of inhalations per day
An earlier trial of the three drugs in two distinct inhalers showed that they considerably enhanced lung function and decreased asthma attacks and symptoms in patients with more serious asthma.
A two-in-one inhaler combines a steroid prevention device with a long-acting bronchodilator such as a long-acting beta2 agonist, but some patients continue to experience asthma attacks, including shortness of breath, wheezing, cough, and tightness of the chest.
The two fresh trials, TRIMARAN, and TRIGGER were conducted over almost two years from 2016 to 2018 and tested two distinct triple therapy strengths in individuals with uncontrolled asthma. A medium corticosteroid strength dose (100 micrograms), a long-acting beta2 agonist (six micrograms) and a muscarinic antagonist (10 micrograms) were obtained in TRIMARAN 579 patients.
The results measured were lung function and whether there were still mild and more serious asthma attacks in patients. Patients inhaled as much air as they could in a second to check lung function, or the degree to which the airways of nurses were obstructed, and a measure of the quantity in milliliters, known as the compulsory expiratory quantity (FEV1), was taken.
Triple therapy was discovered to be better than conventional mixed treatment with two medications to prevent mild to serious asthma attacks.